Strong Top-Line Growth
Revenue grew 21% year-over-year to $403M in Q1 2026, driven by higher visit volumes and better-than-expected total revenue per visit.
Lifestance Health Group
· LFST
May 7th, 2026
Summary
- Earnings Call Date:
- 2026-05-07
- Change Since:
- +9.04%
- Next Earnings Date:
- 2026-08-12
Earnings Call Sentiment
PositiveThe call presents a strong operational and financial quarter with robust revenue growth (+21%), substantial adjusted EBITDA expansion (+48%), meaningful visit and clinician productivity gains, upgraded full-year guidance and positive clinical outcomes. Key investments in technology, AI and a planned EHR transition support long-term margin objectives, and specialty services are accelerating. Near-term headwinds include modest per-visit revenue growth (TRPV +3%), a modest G&A increase for strategic investments, implementation risk from a multi-year EHR rollout, and no immediate measurable improvement in clinician retention. Overall, the positive growth, profitability, cash generation, and upgraded guidance significantly outweigh the highlighted challenges.
Company Guidance
LifeStance raised full‑year 2026 guidance after a strong Q1: revenue guidance was increased by $25 million at the midpoint to $1.64–$1.68 billion (midpoint implying ~17% growth), Center Margin guidance was raised by $21 million at the midpoint to $547–$571 million, and adjusted EBITDA guidance was raised by $15 million at the midpoint to $200–$220 million (midpoint implying a 12.7% adjusted EBITDA margin, >150 bps expansion year‑over‑year). The company noted the outlook assumes revenue growth driven primarily by higher visit volume plus low‑to‑mid‑single‑digit total revenue per visit (TRPV) increases, and reiterated expected stock‑based compensation of ~$60–$70 million for the year. For Q2 management guided to revenue of $405–$425 million, Center Margin of $135–$147 million and adjusted EBITDA of $50–$60 million, and longer‑term targets remain mid‑teens annual revenue growth and mid‑teens adjusted EBITDA margins by FY2028—anchored by Q1 outperformance (Q1 revenue $403M, visits 2.5M +18%, TRPV $163 +3%, adjusted EBITDA $51M, clinician base 8,349 with +309 adds).
Significant Adjusted EBITDA Expansion
Adjusted EBITDA increased 48% year-over-year to $51M in Q1 2026, with an adjusted EBITDA margin of 12.7% for the quarter and a raised full-year adjusted EBITDA guidance of $200M–$220M (midpoint implying 12.7% margin and >150 bps margin expansion YoY).
Visit and Clinician Productivity Gains
Visit volumes rose 18% to 2.5M; visits per average clinician increased 7% YoY for the second consecutive quarter, reflecting sustained productivity initiatives.
Clinician Base Expansion
Net clinician adds of 309 in the quarter brought the clinician base to 8,349 (11% growth YoY), supporting capacity and network scale.
Center Margin and Profitability Improvements
Center Margin grew 24% to $136M and represented 33.7% of revenue, benefiting from rate, operating leverage from volume and favorable center spending.
Improved Net Income and Cash Generation
Net income was positive $14M vs $1M a year ago; free cash flow of $22M improved by $32M YoY. Cash balance ended at $195M with net long-term debt $263M and net leverage 0.5x (gross leverage 1.6x).
Raised Full-Year Guidance and Long-Term Targets
Raised 2026 revenue range midpoint to $1.66B (implying ~17% growth), raised Center Margin and adjusted EBITDA guidance, and reaffirmed mid-teens annual revenue growth longer-term and mid-teens adjusted EBITDA margins by 2028.
Clinical Outcomes and Patient Satisfaction
Published outcomes from ~180,000 patients showing roughly 75% experienced clinically significant improvements in anxiety and depression; patient satisfaction strong with a >4.7/5 Google rating across ~575 centers.
Technology & AI Adoption Driving Operational Improvements
Deployment of digital and AI tools (digital check-in, AI-driven workflows, AI-assisted documentation, AI scheduling) and rollout of Care Matching 2.0 improved inbound-to-booking conversion by ~5%; selected a new EHR vendor with implementation planning starting this year and transition in 2027.
Geographic Expansion and Specialty Service Growth
Opened 6 centers and completed 2 tuck-in acquisitions in Q1; company plans 20–30 new centers in 2026. Specialty revenue expected to grow from ~$50M last year to ~$70M in 2026 (~40% YoY), driven by TMS and Spravato expansion.
Capital Allocation and Share Repurchase Activity
Board authorized $100M share repurchase program; $49M deployed in Q1, reflecting confidence in cash generation and capital allocation priorities.
Operator
Hello, and thank you for standing by. My name is Mark, and I will be your conference operator for today. [Operator Instructions] Thank you. And I would now like to turn the call over to Monica Prokocki. Please go ahead.
Monica Prokocki
Thank you, operator. Good morning, everyone, and welcome to LifeStance Health's First Quarter 2026 Earnings Conference Call. I'm Monica Prokocki, Vice President of Finance and Investor Relations. Joining me today are Dave Bourdon, Chief Executive Officer; and Ryan McGroarty, Chief Financial Officer. We issued the earnings release and presentation before the market opened this morning. Both are available on the Investor Relations section of our website, investor.lifestance.com. In addition, a replay will be available following the call. Before turning over to management for their prepared remarks, please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings.
Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model and strategy. Those statements involve risks, uncertainties and other factors as noted in our periodic filings with the SEC that could cause actual results to differ materially. Please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable GAAP measures is included in the earnings press release tables and presentation appendix...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free